Scientific Publications by FDA Staff
Pediatr Infect Dis J 2013 Oct;32(10):1144-6
Potential for Palivizumab Interference with Commercially Available Antibody-Antigen Based Respiratory Syncytial Virus Diagnostic Assays.
Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in infants. The potential for palivizumab to interfere with commercially available RSV diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.
|Category: Journal Article|
|PubMed ID: #23584584||DOI: 10.1097/INF.0b013e31829561dd|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-04-16||Entry Last Modified: 2013-11-02|